E. Plana

First name
E.
Last name
Plana
Rivero-Ferrer, E., Olesen, M., Plana, E., Aguado, J., Saigi-Morgui, N., Rubino, A., et al. (2022). Characteristics of New Users of Aclidinium Bromide, Aclidinium/Formoterol, and Other COPD Medications in the United Kingdom, Denmark, and Germany. Clin Drug Investig. http://doi.org/10.1007/s40261-022-01120-2
Afonso, A., Schmiedl, S., Becker, C., Tcherny-Lessenot, S., Primatesta, P., Plana, E., et al. (2016). A methodological comparison of two European primary care databases and replication in a US claims database: inhaled long-acting beta-2-agonists and the risk of acute myocardial infarction. Eur J Clin Pharmacol. http://doi.org/10.1007/s00228-016-2071-8
Margulis, A. V., Fortuny, J., Kaye, J. A., Calingaert, B., Reynolds, M., Plana, E., et al. (2018). Value of Free-text Comments for Validating Cancer Cases Using Primary-care Data in the United Kingdom. Epidemiology. http://doi.org/10.1097/ede.0000000000000856
Kaye, J. A., Margulis, A. V., Fortuny, J., McQuay, L. J., Plana, E., Bartsch, J. L., et al. (2017). Cancer Incidence after Initiation of Antimuscarinic Medications for Overactive Bladder in the United Kingdom: Evidence for Protopathic Bias. Pharmacotherapy. http://doi.org/10.1002/phar.1932
Margulis, A. V., Fortuny, J., Kaye, J. A., Calingaert, B., Reynolds, M., Plana, E., et al. (2018). Validation of Cancer Cases Using Primary Care, Cancer Registry, and Hospitalization Data in the United Kingdom. Epidemiology. http://doi.org/10.1097/ede.0000000000000786
Cainzos-Achirica, M., Varas-Lorenzo, C., Pottegard, A., Asmar, J., Plana, E., Rasmussen, L., et al. (2018). Methodological challenges when evaluating potential off-label prescribing of drugs using electronic health care databases: A case study of dabigatran etexilate in Europe. Pharmacoepidemiol Drug Saf. http://doi.org/10.1002/pds.4416
Rebordosa, C., Plana, E., Aguado, J., Thomas, S., Garcia-Gil, E., Perez-Gutthann, S., & Castellsague, J. (2018). GOLD assessment of COPD severity in the Clinical Practice Research Datalink (CPRD). Pharmacoepidemiol Drug Saf. http://doi.org/10.1002/pds.4448
Rebordosa, C., Aguado, J., Plana, E., Thomas, S., Frances, A., Lei, A., et al. (2019). Use of aclidinium did not increase the risk of death in a noninterventional cohort study in the Clinical Practice Research Datalink (CPRD), United Kingdom. Respir Med. http://doi.org/10.1016/j.rmed.2019.04.018
Fortuny, J., Gilsenan, A., Cainzos-Achirica, M., Cantero, O. F., Flynn, R. W. V., Garcia-Rodriguez, L., et al. (2019). Study Design and Cohort Comparability in a Study of Major Cardiovascular Events in New Users of Prucalopride Versus Polyethylene Glycol 3350. Drug Saf. http://doi.org/10.1007/s40264-019-00836-z
Gilsenan, A., Fortuny, J., Cainzos-Achirica, M., Cantero, O. F., Flynn, R. W. V., Garcia-Rodriguez, L., et al. (2019). Cardiovascular Safety of Prucalopride in Patients with Chronic Constipation: A Multinational Population-Based Cohort Study. Drug Saf. http://doi.org/10.1007/s40264-019-00835-0